SERIES P COMMON STOCK PURCHASE WARRANT Seneca Biopharma, Inc.Securities Agreement • January 22nd, 2020 • Neuralstem, Inc. • Biological products, (no disgnostic substances) • New York
THIS SERIES P COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on January 24, 2022 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Seneca Biopharma, Inc., a Delaware corporation (the “Company”), up to _______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SERIES Q COMMON STOCK PURCHASE WARRANT Seneca Biopharma, Inc.Common Stock Purchase Agreement • January 22nd, 2020 • Neuralstem, Inc. • Biological products, (no disgnostic substances) • New York
THIS SERIES Q COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on January 22, 2025 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Seneca Biopharma, Inc., a Delaware corporation (the “Company”), up to _______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT Seneca Biopharma, Inc.Placement Agent Agreement • January 22nd, 2020 • Neuralstem, Inc. • Biological products, (no disgnostic substances) • New York
THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on January 17, 2025 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Seneca Biopharma, Inc., a Delaware corporation (the “Company”), up to _______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to that certain Engagement Agreement, by and between the Company and H.C. Wainwright & Co., LLC, dated as of January 17, 2020.
STRICTLY CONFIDENTIAL Seneca Biopharma, Inc. 20271 Goldenrod Lane, 2nd Floor Germantown, Maryland 20876 Attn: Kenneth Carter, Ph.D., Executive ChairmanExclusive Agency Agreement • January 22nd, 2020 • Neuralstem, Inc. • Biological products, (no disgnostic substances) • New York
This letter agreement (this “Agreement”) constitutes the agreement between Seneca Biopharma, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive agent, advisor or underwriter in any offering that is not made to Excluded Investors, as defined below of securities of the Company (the “Securities”), including but not limited to, restructuring of the Company’s outstanding warrants (each, an “Offering”) during the Term (as hereinafter defined) of this Agreement. Wainwright acknowledges that the Company is currently in discussion with the investors contained on Schedule A (“Excluded Investors”) and that any Securities sold to an Excluded Investor will not be subject to the terms of this Agreement and Wainwright will not be entitled to any compensation associated therewith. The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implie
